Blog
RSS FeedPosted by Michael Wonder on 02 Apr 2020
COVID-19 has changed how the world does science, together
1 April 2020 - Never before, scientists say, have so many of the world’s researchers focused so urgently on a single ...
Posted by Michael Wonder on 31 Mar 2020
Developing COVID-19 vaccines at pandemic speed
30 March 2020 - Rapid publication of a perspective co-authored by former head of Australian Department of Health. ...
Posted by Michael Wonder on 30 Mar 2020
Johnson & Johnson announces a lead vaccine candidate for COVID-19; landmark new partnership with U.S. Department of Health & Human Services; and commitment to supply one billion vaccines worldwide for emergency pandemic use
30 March 2020 - Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020. ...
Posted by Michael Wonder on 25 Mar 2020
Coronavirus drugs, vaccine are many months away, health experts say
24 March 2020 - Public- and private-sector medical officials cautioned that further study is needed to assess possible treatments pushed by ...
Posted by Michael Wonder on 23 Mar 2020
FDA and EMA collaborate to facilitate SARS-CoV-2 vaccine development
23 March 2020 - Vaccines offer a way to build immunity to a disease-causing microorganism before one has ever been exposed ...
Posted by Michael Wonder on 20 Mar 2020
Coronavirus vindicates capitalism
19 March 2020 - Drug companies will save lives, even as Bernie Sanders is denouncing them. ...
Posted by Michael Wonder on 17 Mar 2020
Making a new vaccine is not a race, it is a lottery
17 March 2020 - The COVID-19 novel coronavirus outbreak has challenged global researchers to find a vaccine. ...
Posted by Michael Wonder on 03 Mar 2020
'Get it done. We need it': Trump's coronavirus message to big pharma
3 March 2020 - President Donald Trump sought to show his personal engagement in the fight against coronavirus, meeting with ...
Posted by Michael Wonder on 24 Feb 2020
Seqirus receives FDA approval for Fluad Quadrivalent (influenza vaccine, adjuvanted) for adults 65 years and older
24 February 2020 - Designed with MF59 adjuvant to help strengthen, broaden and lengthen the body's immune response against the influenza ...
Posted by Michael Wonder on 04 Feb 2020
Seqirus announces U.S. FDA approval of its first-ever adjuvanted, cell-based pandemic influenza A (H5N1) vaccine
3 February 2020 - Seqirus, a global leader in influenza prevention and pandemic response, today announced that the U.S. FDA ...
Posted by Michael Wonder on 16 Jan 2020
Novavax granted fast track designation for NanoFlu in older adults
15 January 2020 - Novavax today announced that the U.S. FDA has granted fast track designation for NanoFlu, its recombinant quadrivalent ...
Posted by Michael Wonder on 10 Jan 2020
Meissa Vaccines receives U.S. FDA fast track designation for respiratory syncytial virus vaccine, MV-012-968
10 January 2020 - Meissa Vaccines announced today that the U.S. FDA has granted fast track designation to MV-012-968, an ...
Posted by Michael Wonder on 20 Dec 2019
First FDA approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response
19 December 2019 - The U.S. FDA announced today the approval of Ervebo, the first FDA approved vaccine for the prevention ...
Posted by Michael Wonder on 13 Dec 2019
Y-mAbs’ GD2-GD3 vaccine granted rare paediatric disease designation
12 December 2019 - Y-mAbs Therapeutics today announced that its GD2-GD3 vaccine has been granted a rare paediatric disease designation ...
Posted by Michael Wonder on 05 Nov 2019
FDA approves Fluzone High-Dose quadrivalent (influenza vaccine) for adults 65 years of age and older
4 November 2019 - Will be available in fall 2020, in time for the 2020-2021 flu season. ...